Davis Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Davis Capital Management's XBI Position: Q3 2026 in Review
Davis Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 352 shares worth $55.5K. The position accounts for 0.03% of the portfolio, ranked #147.
Davis Capital Management first reported a position in XBI in Q1 2020 and has held it in 13 quarters since. The position peaked at $55.7K in Q2 2026. 964 funds tracked by Wall St. Rank hold XBI as of Q3 2026.
- Davis Capital Management held 352 shares of State Street SPDR S&P Biotech ETF worth $55.5K as of Q3 2026.
- Davis Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
- State Street SPDR S&P Biotech ETF made up 0.03% of Davis Capital Management's portfolio in Q3 2026, its #147 holding.
- Davis Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 13 quarters since.
- Davis Capital Management's State Street SPDR S&P Biotech ETF position peaked at $55.7K in Q2 2026.
- 964 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.
Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.